drugset / Trial / NCT00004744
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis
Phase 3
Completed
76 enrolled
National Institute of Neurological Disorders and Stroke (NINDS)
Mayo Clinic · collab
RandomizedDouble-blindTreatment
Summary
OBJECTIVES: I. Determine whether high-dose intravenous immune globulin (IVIG) is more effective than placebo in restoring neurologic function (muscle strength) in patients with multiple sclerosis. II. Determine the time to recovery following IVIG.
Timeline
- Start
- 1993-02
- Primary completion
- 1998-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | Intravenous |